MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

The latest financial statement is for the quarter ending 2025-09-30.

Cash Flow Overview

Free Cash flow
-$31,618K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Revenue from collaboration agreements
24,931 -
Total operating expenses
117,008 -
Non-operating income
7,569 -
Net loss
-32,166 -52,342
Stock-based compensation expense
4,593 10,499
Impairment of long-lived assets
10,733 -
Depreciation and amortization expense
460 1,071
Reduction in carrying amount of right-of-use asset
1,688 3,317
Net accretion of discounts on marketable securities
515 1,364
Other
30 48
Accounts receivable
4,341 -901
Prepaid expenses and other current and long-term assets
572 -3,974
Accounts payable
-885 889
Accrued expenses and other current liabilities
-2,015 -6,103
Operating lease liability
-1,461 -2,833
Deferred revenue
-6,756 -3,399
Net cash used in operating activities
-31,207 -45,342
Proceeds from maturities of marketable securities
51,180 115,551
Purchases of marketable securities
46,683 47,320
Purchases of property and equipment, net
411 185
Net cash provided by (used in) investing activities
4,086 68,046
Proceeds from issuance of common stock-At The Market
7,526 0
Proceeds from issuance of common stock-Stock Purchase Agreement
0 0
Proceeds from exercise of stock options
107 0
Payments for repurchase of common stock for tax withholding
24 155
Other
164 109
Net cash provided by financing activities
7,773 -46
Net change in cash, cash equivalents and restricted cash
-19,348 22,658
Cash and cash equivalents at beginning of period
58,942 -
Cash and cash equivalents at end of period
62,252 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

C4 Therapeutics, Inc. (CCCC)

C4 Therapeutics, Inc. (CCCC)